Octreotide
Also known as: Sandostatin, Sandostatin Lar Depot.
Wholesale (NADAC) cost for every strength and dosage form — the price pharmacies pay, published weekly by CMS. Not your out-of-pocket price.
Wholesale (NADAC) prices — every strength & form
| Strength | Form | NADAC / unit | Package | Class |
|---|---|---|---|---|
| 10 MG | (unspecified) | $3,387.53 / unit | — | Brand |
| 10 MG | Vial | $3,387.53 / unit† | — | Brand |
| 20 MG | (unspecified) | $4,412.06 / unit | — | Brand |
| 20 MG | Vial | $4,412.06 / unit† | — | Brand |
| 30 MG | (unspecified) | $6,680.85 / unit | — | Brand |
| 30 MG | Vial | $6,680.85 / unit† | — | Brand |
| 50 MCG/ML | Vial | $2.64 / mL† | — | Generic |
| 100 MCG/ML | Vial | $2.74 / mL† | — | Generic |
| 1000 MCG/5 ML | Vial | $5.34 / mL† | — | Generic |
Wholesale (NADAC) — the price pharmacies pay, not your out-of-pocket price. Brand list prices fall after confidential rebates. † Package size not curated yet — priced per single unit/mL, not per full pen, inhaler, or vial.
NADAC week of 2026-07-01 · updated weekly · source CMS
Medicaid & Medicare spending · 2024
In 2024, Medicaid paid $37,674,966 gross for Octreotide across 11,411 prescriptions (measured, national).
Medicare Part D EST spent an estimated ~$5,571,056 gross (retail pharmacy only; excludes Part B).
Gross program spending, before rebates — not what patients pay out of pocket. Brand net cost is materially lower after confidential rebates; generics are close to net.
Source: Medicaid SDUD 2024 · Medicare Part D 2024 · CMS